Anatara Lifesciences Ltd has released a press release.
Appendix 4C & Q4 FY24 Activities Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Anatara Lifesciences Ltd on 6ix
Story so far
Earlier from Anatara Lifesciences
- Anatara successful placement for $1.0M
- Recruitment for Pivotal Phase II IBS Clinical Trial Stage 2
- Appendix 4D & Half Year Report 31 December 2023
- Appendix 4C & Q2 FY24 Activities Report
- Entitlement Offer Results
Later from Anatara Lifesciences
- Appendix 4E & Financial Report 30 June 2024
- $626,000 received in R&D Tax Incentive for FY24
- GaRP Irritable Bowel Syndrome Clinical Trial Update
- Anatara's GaRP granted EU patent
- GaRP-IBS Irritable Bowel Syndrome Clinical Trial Update
Follow Anatara Lifesciences into a list and get an email when it puts out news.
Follow Anatara Lifesciences